5J30 Stock Chart & Stats
€0.04
<€0.01(5.00%)
At close: 4:00 PM EST
€0.04
<€0.01(5.00%)
Day’s Range― - ―
52-Week Range€0.26 - €4.44
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€17.32M
Enterprise Value€318.37
Total Cash (Recent Filing)€37.15M
Total Debt (Recent Filing)€23.21M
Price to Earnings (P/E)―
Beta15.04
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.91
Shares Outstanding10,225,300
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.76
Revenue Forecast (FY)€6.00M
Bulls Say, Bears Say
Bulls Say
Improving Revenue GrowthTTM revenue growth of about 14.2%, following only approximately 0.4% growth in 2025, indicates improving commercial momentum. If sustained, expanding adoption can increase operating scale and help the company leverage its established medical-device platform over the next several quarters.
Healthy Gross MarginA gross margin near 59% provides meaningful contribution from each unit of revenue before operating costs. This suggests the Nevisense business has viable product economics, giving SciBase a foundation to improve profitability if revenue growth continues and operating expenses become better aligned with scale.
Recurring Usage Revenue ModelThe combination of upfront device placements and repeat revenue from consumables, procedures, maintenance, training, and support can deepen customer value over time. Greater utilization by installed clinical customers may create a more durable revenue base than one-time equipment sales alone.
Bears Say
Persistent Deep LossesA net margin near negative 208% shows that the current cost base remains far ahead of revenue scale. Persistent losses can delay self-funded expansion, constrain strategic flexibility, and make future profitability dependent on substantial revenue growth or difficult cost reductions.
Severe Cash BurnStrongly negative operating and free cash flow indicate that the business is consuming substantial cash while it expands. Continued burn can require external financing before operating performance improves, increasing funding dependence and potentially limiting investment in commercial growth or product development.
Volatile Leverage And Funding RiskAlthough current leverage is moderate, the sharp prior increase shows that the balance sheet can weaken materially when losses persist. Any renewed equity pressure could raise borrowing or dilution risk, reducing financial resilience and making long-term execution more dependent on external capital.
5J30 FAQ
What was SciBase Holding AB’s price range in the past 12 months?
SciBase Holding AB lowest stock price was €0.26 and its highest was €4.44 in the past 12 months.
What is SciBase Holding AB’s market cap?
SciBase Holding AB’s market cap is €17.32M.
When is SciBase Holding AB’s upcoming earnings report date?
SciBase Holding AB’s upcoming earnings report date is Nov 12, 2026 which is in 65 days.
How were SciBase Holding AB’s earnings last quarter?
SciBase Holding AB released its earnings results on Aug 19, 2026. The company reported -€0.254 earnings per share for the quarter.
Is SciBase Holding AB overvalued?
According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued.
Does SciBase Holding AB pay dividends?
SciBase Holding AB does not currently pay dividends.
What is SciBase Holding AB’s EPS estimate?
SciBase Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciBase Holding AB have?
SciBase Holding AB has 10,225,300 shares outstanding.
What happened to SciBase Holding AB’s price movement after its last earnings report?
SciBase Holding AB reported an EPS of -€0.254 in its last earnings report. Following the earnings report the stock price went down -2.137%.
Which hedge fund is a major shareholder of SciBase Holding AB?
Currently, no hedge funds are holding shares in DE:5J30
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciBase Holding AB
SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their key offerings, Nevisense and Nevisense Go, comprise a point-of-care platform designed for the detection of melanoma and non-melanoma skin cancers, as well as for evaluating skin barrier function. The company also maintains a collaborative agreement with the Advanced Dermatology and Cosmetic Surgery (ADCS) group.